Search Results for "vaccine, adult"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for vaccine, adult. Results 91 to 100 of 293 total matches.
See also: MMR II

COVID-19 Update: New Pfizer and Moderna Vaccine Formulations for 2024-2025

   
The Medical Letter on Drugs and Therapeutics • Sep 16, 2024  (Issue 1711)
and pericarditis after receipt of COVID-19 vaccines among adolescents and young adults. October 10, 2023 ...
New 2024-2025 formulations of the mRNA COVID-19 vaccines manufactured by Pfizer/BioNTech (Comirnaty) and Moderna (Spikevax) that more closely target currently circulating variants have been licensed by the FDA for persons ≥12 years old and made available under FDA Emergency Use Authorizations (EUAs) for use in persons 6 months to 11 years old.1-3 A 2024-2025 formulation of the adjuvanted protein subunit COVID-19 vaccine manufactured by Novavax is expected to become available soon for persons ≥12 years old.
Med Lett Drugs Ther. 2024 Sep 16;66(1711):151-2   doi:10.58347/tml.2024.1711c |  Show IntroductionHide Introduction

BioThrax and Anthrasil for Anthrax

   
The Medical Letter on Drugs and Therapeutics • May 09, 2016  (Issue 1494)
immune globulin (Anthrasil – Emergent BioSolutions) for treatment of inhalation anthrax in adults ...
The FDA has approved anthrax vaccine adsorbed (AVA; BioThrax – Emergent BioSolutions) for prevention of anthrax disease in adults following exposure to Bacillus anthracis and intravenous anthrax immune globulin (Anthrasil – Emergent BioSolutions) for treatment of inhalation anthrax in adults and children. AVA has been available since 1970 for prevention of anthrax disease in persons at high risk of exposure.
Med Lett Drugs Ther. 2016 May 9;58(1494):62 |  Show IntroductionHide Introduction

COVID-19 Updates

   
The Medical Letter on Drugs and Therapeutics • Feb 21, 2022  (Issue 1644)
trial in 562 nonhospitalized, SARS-CoV-2-positive adults who had developed symptoms of COVID-19 ≤7 ...
The IV antiviral drug remdesivir (Veklury – Gilead) has been available for treatment of COVID-19 in hospitalized patients since 2020. Now, the FDA has approved remdesivir for treatment of mild to moderate COVID-19 in outpatients ≥12 years old who weigh ≥40 kg and are at high risk for progression to severe disease, including hospitalization or death; they also issued an Emergency Use Authorization (EUA) allowing its use in any other high-risk outpatient who weighs ≥3.5 kg.
Med Lett Drugs Ther. 2022 Feb 21;64(1644):31-2 |  Show IntroductionHide Introduction

Another Subcutaneous Immune Globulin (Cuvitru) for Primary Immunodeficiency (online only)

   
The Medical Letter on Drugs and Therapeutics • May 22, 2017  (Issue 1521)
-policy. 2. Approved for use in adults. 3. For patients switching from immune globulin intravenous (IGIV ...
The FDA has approved a subcutaneously administered 20% solution of human immune globulin (Cuvitru – Shire) for replacement therapy in patients ≥2 years old with a primary humoral immunodeficiency. Hizentra (CSL Behring), another subcutaneously administered 20% immune globulin solution, was approved in 2010 for the same indication. The IgG component of Cuvitru is similar to that of Gammagard Liquid and HyQvia, two subcutaneously administered 10% immune globulin formulations also manufactured by Shire and approved for treatment of primary...
Med Lett Drugs Ther. 2017 May 22;59(1521):e88-9 |  Show IntroductionHide Introduction

Mumps Outbreak

   
The Medical Letter on Drugs and Therapeutics • Mar 17, 2014  (Issue 1438)
in the US have occurred predominantly in vaccinated older teenagers and young adults who are ≥10 years past their last ...
An outbreak of mumps has occurred among students at Fordham University in New York. All of those who developed mumps had been vaccinated against the disease.
Med Lett Drugs Ther. 2014 Mar 17;56(1438):21 |  Show IntroductionHide Introduction

COVID Update: Bivalent Vaccine Booster Doses Authorized for Children ≥5 Years Old (online only)

   
The Medical Letter on Drugs and Therapeutics • Oct 17, 2022  (Issue 1661)
are not authorized for primary immunization against COVID-19. The monovalent Pfizer and Moderna COVID-19 vaccines ...
The FDA has expanded its Emergency Use Authorizations (EUAs) for the COVID-19 vaccines manufactured by Pfizer/BioNTech (Comirnaty) and Moderna (Spikevax) to permit use of the bivalent formulations of these products (containing mRNA from the original and BA.4/5 Omicron strains of SARS-CoV-2) as a booster dose in children as young as 5 years old (Pfizer) or 6 years old (Moderna). The bivalent Pfizer vaccine had previously been authorized for use in persons ≥12 years old and the bivalent Moderna vaccine in persons ≥18 years old. Bivalent vaccines are not authorized for...
Med Lett Drugs Ther. 2022 Oct 17;64(1661):e1 |  Show IntroductionHide Introduction

In Brief: Pfizer/BioNTech COVID-19 Vaccine Authorized for Adolescents 12-15 Years Old

   
The Medical Letter on Drugs and Therapeutics • May 31, 2021  (Issue 1625)
In Brief: Pfizer/BioNTech COVID-19 Vaccine Authorized for Adolescents 12-15 Years Old ...
On May 10, 2021, the FDA expanded its Emergency Use Authorization (EUA) for the Pfizer/BioNTech mRNA-based COVID-19 vaccine to include adolescents 12-15 years old.1The vaccine has been authorized for use in persons ≥16 years old since December 2020.
Med Lett Drugs Ther. 2021 May 31;63(1625):81 |  Show IntroductionHide Introduction

Rimantadine for Prevention and Treatment of Influenza

   
The Medical Letter on Drugs and Therapeutics • Nov 26, 1993  (Issue 910)
in the vaccine, or if vaccine is unlikely to produce an adequate immune response, as in patients ...
Rimantadine hydrochloride (Flumadine - Forest), the alpha-methyl derivative of amantadine (Symmetrel, and others), was recently approved by the US Food and Drug Administration for prevention and treatment of influenza A virus infections in adults and for prevention of influenza in children.
Med Lett Drugs Ther. 1993 Nov 26;35(910):109-10 |  Show IntroductionHide Introduction

COVID-19 Update: Bivalent Pfizer and Moderna Vaccines Authorized for Children ≥6 Months Old (Online Only)

   
The Medical Letter on Drugs and Therapeutics • Dec 12, 2022  (Issue 1665)
vaccine are not currently eligible for booster immunization.1,4 The CDC recommends that children 6 ...
The FDA has expanded its Emergency Use Authorizations (EUAs) for the COVID-19 vaccines manufactured by Pfizer/BioNTech (Comirnaty) and Moderna (Spikevax) to permit use of the bivalent formulations of these products (containing mRNA from the original and BA.4/5 Omicron strains of SARS-CoV-2) in children as young as 6 months. The bivalent Pfizer vaccine is authorized for use as the final dose of a 3-dose primary series in children 6 months to 4 years old. The bivalent Moderna vaccine is authorized for use as a booster dose in children 6 months to 5 years old who completed a primary...
Med Lett Drugs Ther. 2022 Dec 12;64(1665):e209-10 |  Show IntroductionHide Introduction

COVID-19 Updates

   
The Medical Letter on Drugs and Therapeutics • Apr 18, 2022  (Issue 1648)
booster vaccine and Covid-19 mortality in adults 60 to 100 years old. Research Square 2022 March 24 ...
The FDA has expanded the Emergency Use Authorizations (EUAs) for the mRNA COVID-19 vaccines manufactured by Pfizer-BioNTech (Comirnaty) and Moderna (Spikevax) to allow for their use as a second booster dose ≥4 months after a first booster dose in adults ≥50 years old and in persons aged ≥12 years (Pfizer) or ≥18 years (Moderna) who have undergone solid organ transplantation or have a condition that compromises the immune system to a similar extent.
Med Lett Drugs Ther. 2022 Apr 18;64(1648):63-4 |  Show IntroductionHide Introduction